Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.1052W HIGH $7.78
Volume
28.12 K
Value Traded
170.69 K
Short % Float
2.89%
Days to Cover
1.0
-5.44%Week
+43.4%1 Month
+90%3 Month
+39.45%6 Month
-98.71%5 Year
-99.05%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
11.71 M
EPS (TTM)
-12.19
P/E Ratio
-
Ent. Value
-3.09 M
Total Shares
1.93 M
Float Shares
1.64 M
Insiders
14.93%
Institutions
41.98%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
BOLT Catalyst Timeline
Dated clinical, regulatory and corporate events for Bolt Biotherapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Bolt Biotherapeutics, Inc.
215Total events
10Upcoming
28Tier-1 (high impact)
2020 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲Trial InitiationPRA-216Trial
Phase 2 studies initiated with PRA-216 in asthma, atopic dermatitis and COPD
asthma, atopic dermatitis and chronic obstructive pulmonary diseasesource ↗
●Management ChangeCorporate
Sheila Gujrathi appointed Chief Strategy Officer and joins Bolt Board
●Management ChangeCorporate
Sheila Gujrathi appointed Chief Strategy Officer and Board member
◆Topline ReadoutBDC-4182Clinical Data
Initial clinical data for BDC-4182 expected with 3Q 2026 results
◆Oral PresentationBDC-4182Presentation
Initial data from Phase 1 dose-escalation study of BDC-4182 expected
gastric and gastroesophageal cancersource ↗
▲Late-BreakerPRA-216Presentation
PRA-216 Phase 1 healthy volunteer data presented as late-breaking abstract at 2026 ERS
healthy volunteerssource ↗
◆Enrollment UpdateBDC-4182Trial
Actively enrolling patients in Phase 1 dose-escalation study of BDC-4182
gastric and gastroesophageal cancersource ↗
●Trial CompletionBDC-3042Trial
First-in-human Phase 1 dose escalation trial of BDC-3042 completed
cancersource ↗
◆Protocol AmendmentBDC-4182Trial
Protocol modification to allow step-up dosing for BDC-4182 Phase 1 trial
gastric and gastroesophageal cancersource ↗
▲First Patient DosedBDC-4182Trial
BDC-4182 Phase 1 dose-escalation study now enrolling patients
gastric and gastroesophageal cancersource ↗
◆Enrollment UpdateBDC-4182Trial
BDC-4182 Phase 1 study to expand to other countries in 2H 2025
gastric and gastroesophageal cancersource ↗
◆Oral PresentationBDC-3042Presentation
KOL conference call and webcast to discuss BDC-3042 Phase 1 results
cancersource ↗
◆Poster PresentationPresentation
Preclinical data on CEA-targeted Boltbody ISAC at AACR 2025
colorectal, pancreatic and lung tumorssource ↗
◆Poster PresentationBDC-3042Presentation
BDC-3042 Phase 1 dose-escalation data presentation at AACR 2025
advanced solid tumors including NSCLCsource ↗
◆Oral PresentationBDC-3042Presentation
Results from Phase 1 dose-escalation study of BDC-3042 presented at AACR 2025
cancersource ↗
▲Topline ReadoutBDC-3042Clinical Data
Phase 1 dose-escalation data cut-off April 7, 2025
cancersource ↗
▲Trial InitiationBDC-4182Trial
BDC-4182 Phase 1 study opened for enrollment
gastric and gastroesophageal cancersource ↗
◆Oral PresentationBDC-3042Presentation
BDC-3042 Phase 1 results presented at AACR Annual Meeting
cancersource ↗
◆Topline ReadoutBDC-3042Clinical Data
BDC-3042 Phase 1 results to be reported at medical meeting
advanced solid tumorssource ↗
▲Enrollment CompleteBDC-3042Trial
BDC-3042 Phase 1 dose-escalation data presented at AACR 2025
solid tumors including NSCLCsource ↗
◆Oral PresentationPresentation
Preclinical results for next-generation Boltbody ISACs targeting CEA and PD-L1 presented at AACR 2025
cancersource ↗
▲Enrollment CompleteBDC-3042Trial
BDC-3042 Phase 1 dose escalation trial fully enrolled highest dose cohort
advanced solid tumorssource ↗
▲Partnership / LicenseCorporate
Bolt and Toray announce co-development collaboration targeting Caprin-1
solid tumorssource ↗
◆Trial InitiationTRK-950Trial
Phase 2 clinical trial in gastric cancer currently ongoing
gastric cancersource ↗
▲First Patient DosedBDC-4182Trial
First patient dosed in BDC-4182 clinical trial expected in 2025
cancer (claudin 18.2 positive tumors)source ↗
◆Trial InitiationBDC-4182Trial
Initiation of clinical trials for BDC-4182 expected in 2025
solid tumors (claudin 18.2 positive)source ↗
●IND SubmissionBDC-4182IND
IND submission for BDC-4182 expected in 2025
cancer (claudin 18.2-expressing tumors)source ↗
◆Timing GuidanceBDC-4182Presentation
Initiation of clinical trials for BDC-4182 expected in 2025
cancer (Claudin 18.2 positive tumors)source ↗
●Oral PresentationBDC-4182Presentation
Presented updated preclinical activity of BDC-4182 at SITC 39th Annual Meeting
cancer (claudin 18.2 positive tumors)source ↗
Past FDA Catalysts and PDUFA Decisions
How BOLT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | BDC-4182 | Phase 1/2 data readout | Phase 1/2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 93%
Micro Cap(rank 639 of 687)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BDC-4182 Antibody-Drug Conjugates (ADCs)NCT06921837 | Gastric Cancer Adenocarcinoma Metastatic | Phase 1/2 | RECRUITING | 122 | May 1, 2029 |
Clinical Trial Results
Readouts, endpoints and source filings for every BOLT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| BDC-3042 | metastatic or unresectable solid tumors including non-small cell lung cancer (NSCLC) | Phase 1 | 2025-05-12 | 10 mg/kg q2w as a recommended Phase 2 dose (RP2D)Read More | Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update • BDC-4182 Phase 1 dose-escalation study now open for enrollment • BDC-3042 Phase 1 dose-escalation data presenRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Coastlands Capital LP10% Owner | Buy | 50,000 462,416 held | $6.38 | 11/09/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BOLT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Sofinnova Investments, Inc. | 0 % | 530.23 K | 137.72 K |
Ownership Trends
BOLT Short Interest
Shares sold short, counted twice a month.
2.89%
Short % of Float
of tradable shares sold short
47.4K
Shares Sold Short
+200.8% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
1.3M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BOLT ranks across every disease it competes in
Competitive Position is a premium feature
See how BOLT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBOLT News
BOLT▲ +2.9%today
Bolt Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Bolt Biotherapeutics reported its third quarter 2026 financial results, highlighting the acquisition of Prana Therapies and a $120 million private placement financing. The company is now focusing on PRA-216, a bispecific antibody in Phase 2 studies for asthma, COPD, and atopic dermatitis, with initial data expected in 2Q 2027. The cash runway is projected to support operations into 2028.
Read more →BOLT▲ +5.3%on this news
Bolt Biotherapeutics to Participate in Upcoming Conferences
Bolt Biotherapeutics announced its participation in two upcoming investor conferences. Sheila Gujrathi, M.D., will present at the Stifel 2026 Healthcare Conference on November 10 and attend the Jefferies Global Healthcare Conference from November 16-19. The company is focused on advancing its lead program, PRA-216, currently in Phase 2 development.
Read more →BOLT▲ +49.6%on this news
Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory Indications
Bolt Biotherapeutics announced the acquisition of Prana Therapies and a $120 million private placement to advance its pipeline, particularly PRA-216, a bispecific antibody in Phase 2 trials for asthma and other conditions. The financing is expected to fund operations through 2028. Sheila Gujrathi, former CEO of Prana, will join Bolt's leadership team.
Read more →BOLT▼ -13.3%on this news
Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Bolt Biotherapeutics reported a second quarter operating loss of $8.4 million and collaboration revenue of just $5,000. The company holds $18.1 million in cash, which it expects to last into the first quarter of 2027. Clinical development continues for its lead candidate BDC-4182 in gastric cancer patients. Initial data from the ongoing Phase 1/2 trial is scheduled for release with the third quarter results.
Read more →BOLTBolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Bolt Biotherapeutics reported its first quarter 2026 financial results, highlighting the ongoing Phase 1/2 study of BDC-4182, an immune-stimulating antibody conjugate. The company has a cash balance of $23.9 million, expected to support operations into 2027. Initial clinical data from the study is anticipated in the third quarter of 2026. However, collaboration revenue has significantly decreased compared to the previous year.
Read more →BOLTBolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
Bolt Biotherapeutics reported its fourth quarter and full-year 2025 financial results, highlighting the promising early results of BDC-4182, a next-generation immune-stimulating antibody conjugate. The company is currently enrolling patients in a Phase 1 trial targeting gastric and gastroesophageal cancers, with initial data expected in Q3 2026. The report also emphasizes the innovative nature of the Boltbody ISAC platform in cancer treatment.
Read more →BOLTBolt Biotherapeutics to Participate in Upcoming March Conferences
Bolt Biotherapeutics will participate in two conferences in March 2026, showcasing its commitment to advancing cancer treatments. The company is known for its innovative Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) technology, currently in clinical trials for gastric and gastroesophageal cancers. Additionally, Bolt is exploring partnerships for its Dectin-2 agonist and preclinical ISAC programs.
Read more →BOLTBolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Bolt Biotherapeutics reported a third quarter operating loss of $7.7 million, down from $16.4 million a year earlier. The company held $38.8 million in cash as of September 30, 2025. This balance is expected to fund operations and key milestones through 2027. Initial clinical data for its BDC-4182 program is anticipated in the third quarter of 2026.
Read more →BOLT▼ -12.4%on this news
Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027
Bolt Biotherapeutics has provided an update on its Phase 1 study of BDC-4182, noting a strong immune response at initial dose levels. The company plans to modify the trial protocol for better dosing strategies and expects to report initial data in Q3 2026. However, to extend its cash runway into 2027, Bolt is reducing its workforce by about 50%.
Read more →BOLTBolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Bolt Biotherapeutics reported its financial results for Q2 2025, highlighting the initiation of a Phase 1 study for BDC-4182, targeting gastric and gastroesophageal cancer. The company has a robust cash balance of $48.5 million, expected to support key milestones through mid-2026. Despite the progress, the company faced a $9.2 million loss from operations and is looking for a partner for the further development of BDC-3042. Additionally, previous restructuring efforts have led to decreased expenses across various operational aspects.
Read more →BOLTBolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Bolt Biotherapeutics has reported its first quarter 2025 financial results, highlighting advancements in its immunotherapy pipeline. The company has opened enrollment for the BDC-4182 Phase 1 study and presented encouraging data for BDC-3042, including favorable safety profiles. Collaboration revenue has decreased significantly, with a loss from operations reported at $12.1 million. The company maintains a cash balance of $58 million, which is projected to support operations through mid-2026.
Read more →BOLTBolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates
Bolt Biotherapeutics will host a KOL conference call on May 12, 2025, to discuss Phase 1 results of BDC-3042. Dr. Ecaterina Dumbrava from MD Anderson will present findings from the recent AACR Annual Meeting. The management team will also cover partnering plans and updates on BDC-4182 and financial results for Q1 2025.
Read more →BOLTBolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025
Bolt Biotherapeutics presented promising preclinical results for its next-generation Boltbody ISACs targeting CEA and PD-L1 at the AACR Annual Meeting. The CEA-targeted ISAC showed complete and durable anti-tumor responses in mice and was well-tolerated in non-human primates. The PD-L1 ISAC demonstrated a novel mechanism of action, potentially enhancing cancer treatment strategies.
Read more →BOLTBolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
Bolt Biotherapeutics presented promising results from its Phase 1 study of BDC-3042 at the AACR Annual Meeting 2025. The drug showed a favorable safety profile and biological activity, with signs of anti-tumor effects in patients with non-small cell lung cancer. The company is seeking partners to advance the development of BDC-3042, which targets dectin-2 to activate immune responses.
Read more →BOLTBolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
Bolt Biotherapeutics has announced that it will present data from its Phase 1 dose-escalation clinical study of BDC-3042 at the upcoming AACR Annual Meeting in April 2025. BDC-3042 is an innovative immunotherapy targeting dectin-2, aimed at treating patients with advanced solid tumors, including non-small cell lung cancer. Additionally, the company will share preclinical data on other projects, showcasing its commitment to advancing cancer treatments. The meeting serves as a platform for sharing significant findings in cancer research and treatment development.
Read more →BOLTBolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
Bolt Biotherapeutics has reported its fourth quarter and full-year financial results for 2024, highlighting significant advancements in its clinical pipeline. The company anticipates that BDC-4182 will enter clinical trials for gastric cancer by the second quarter of 2025. Additionally, the Phase 1 study of BDC-3042 is fully enrolled without any dose-limiting toxicities, and results will be reported in the same timeframe. Despite these positive developments, the company faced challenges with zero collaboration revenue this past quarter and a substantial loss from operations.
Read more →BOLTBolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.
Bolt Biotherapeutics, Inc. has announced its collaboration with Toray Industries, Inc. to co-develop a cancer immunotherapy targeting Caprin-1, a novel antigen expressed in solid tumors. This partnership leverages Bolt's Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) technology alongside Toray's monoclonal antibody TRK-950, which is currently in Phase 2 trials for gastric cancer. The collaboration aims to enhance treatment options for patients with difficult-to-manage cancers while utilizing both companies' expertise in immunotherapy. This strategic alliance is seen as a significant step towards improving cancer care and outcomes.
Read more →BOLTBolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update • Advanced to the highest dose level in the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanc
Bolt Biotherapeutics reported its third quarter financial results for 2024, announcing progress in clinical trials for its cancer therapies BDC-3042 and BDC-4182. The company advanced to the highest dose level in the Phase 1 study of BDC-3042 and is preparing for clinical trials of BDC-4182, which is expected to begin in the second quarter of 2025. The firm reported a cash balance of $84.4 million, projected to support operations through mid-2026, although collaboration revenue showed a decrease from the previous year.
Read more →BOLTBolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting
Bolt Biotherapeutics presented updated preclinical data for BDC-4182 and insights from its Phase 1 dose-escalation trial of BDC-1001 at the SITC Annual Meeting. BDC-4182 exhibited strong anti-tumor activity and was shown to be safer compared to existing claudin 18.2 ADC treatments. Additionally, learnings from BDC-1001 support the hypothesis that improved immune activation in ISACs may lead to greater treatment efficacy. Clinical trials for BDC-4182 are anticipated to commence in 2025.
Read more →About Bolt Biotherapeutics, Inc.
Headquarters900 CHESAPEAKE DRIVE, REDWOOD CITY, CA, 94063
BIOPHARMAWATCH ELITE
Trade the next BOLT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime